Require public disclosure of drug prices and PBM rebates
Prescription Drug Price Transparency Act
Plain-language summary
This bill targets the opacity of drug pricing rather than setting prices directly. Manufacturers that raise a list price faster than inflation must file a public justification; pharmacy benefit managers must show employers the rebates they negotiate; and HHS must publish what payers actually pay for the 500 most-prescribed drugs. It passed the House 289–141 and awaits Senate committee action.
AI-generated explanation. Review the official text and official sources before drawing conclusions — summaries can omit important detail.
The strongest case on each side
No one in the drug supply chain — not patients, not employers, often not even insurers — can see the real net price of a medicine, which makes market discipline impossible. Transparency is the minimum precondition for any pricing reform and imposes no price controls.
Publishing negotiated rebates can raise prices: economic evidence from other industries shows that when every seller sees competitors' discounts, discounts shrink toward the disclosed benchmark. Justification filings become boilerplate while adding real administrative cost.
Both cases are presented in their strongest form. Quorly does not take a side.
What it changes — and what it doesn't
- •Public justification filings for list-price increases above inflation
- •PBM rebate structures disclosed to employer plan sponsors
- •HHS consumer dashboard of net prices for the 500 most-prescribed drugs
- ○Does NOT set, cap, or negotiate any drug price
- ○Does NOT change patent or exclusivity rules
Recorded votes
Party breakdown is an estimated demonstration visual.
Timeline
- Jun 10, 2025Introduced in the House by Rep. Alicia Nguyen (D)
- Dec 3, 2025Reported out of Energy & Commerce, 34–18
- Apr 16, 2026Passed the House, 289–141
- Apr 30, 2026Referred to Senate HELP Committee
Discussion
The committee calendar is the tell here. Watch whether a markup actually gets scheduled before the August recess — floor speeches are noise, markup dates are signal.
Cosponsor count has been the best single predictor in my model this cycle. Cross the ~200 mark in the House and passage odds roughly double, controlling for committee.
Worth reading the strongest-against section before taking a position — the implementation questions are where most bills like this actually stall, not the politics.
Sponsor
Community sentiment
LivePublic Pulse demonstration sample · not a scientific poll
Related forecast markets
No linked forecast markets for this bill yet.